Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
224
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Marina Deodatoa Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0010-6107
ORCID Icon,
Anna Maria Frustacia Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
,
Paolo Sportolettib Department of Medicine and Surgery, Institute of Hematology, Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy
,
Luca Laurentic Institute of Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
,
Roberta Murrud Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, Cagliari, Italy
,
Andrea Visentine Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy
,
Gianluigi Redaf U.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
,
Francesca Romana Maurog Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Roma, Italy
,
Giulia Quaresminih USC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy
,
Anna Vanazzii Division of Clinical Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
,
Candida Vitalej Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, Università di Torino, Torino, ItalyORCID Iconhttps://orcid.org/0000-0002-2592-8724
ORCID Icon,
Lorella Orsuccik S.C. Ematologia, AOU Città della Salute e della Scienza, Torino, Italy
,
Massimo Massaial Hematology Unit, ASO Santa Croce e Carle, Cuneo, Italy
,
Alessandro Sannam Hematology, Department of Oncology, AOU Careggi, Florence, Italy
,
Marina Mottan Hematology Department, ASST Spedali Civili, Brescia, Italy
,
Adalberto Ibaticio Hematology Unit and Bone Marrow Transplantation, IRCCS Ospedale Policlinico San Martino, Genova, Italy
,
Isacco Ferrarinip Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
,
Chiara Borellaq Hematology Department, San Gerardo Hospital, ASST Monza, Monza, Italy
,
Marzia Varettonir Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Monica Tanis U.O.C. di Ematologia Ospedale Santa Maria delle Croci, Ravenna, Italy
,
Sara Marinonit UOC Ematologia, ASST Ovest milanese, Ospedale di Legnano, Legnano, Italy
,
Andrea Ferrariou UO Ematologia, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
,
Giulia Zamprognaa Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
,
Marco Montilloa Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
&
Alessandra Tedeschia Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
 show all
Pages 1985-1988 | Received 17 Jan 2022, Accepted 08 Mar 2022, Published online: 27 Mar 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

AIRC IG 21744 to MM Project.

Disclosure statement

AMF: consultancy for Janssen, AbbVie, AstraZeneca, BeiGene. PS: board membership for Janssen, AbbVie, AstraZeneca; payment for lectures including service on speaking bureaus from AbbVie. RM: consultancy for AbbVie, AstraZeneca, Janssen. AV: participation in advisory board for AbbVie, Janssen. GR: consultancy for AbbVie, AstraZeneca, BeiGene, Janssen. FRM: consultancy for AbbVie, Janssen, BeiGene, AstraZeneca, Takeda. CV: consultancy fees and participation in advisory board for Janssen. MM: participation in advisory board for Janssen, AbbVie, Roche, Sanofi. AS: consultancy fees and participation in advisory board for Janssen, AbbVie; participation in advisory board for AstraZeneca, Takeda. MV: participation in advisory board for AbbVie, AstraZeneca, BeiGene, Janssen. MM: payment for lectures including service on speaking bureaus from AbbVie, Janssen. AT: payment for lectures including service on speaking bureaus from AbbVie, Janssen, BeiGene; board membership for Janssen, AbbVie, AstraZeneca, BeiGene.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.